Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
2 reports, 1 independent
Updated Sep 3
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Merck's revenue growth trails J&J's, while the FDA approved its LIPFENDRA drug.1 source
- Eli Lilly outperformed Johnson & Johnson stock over the past year.Sub-event
J&J stock outperformed AbbVie; Eli Lilly results surpassed AbbVie fundamentals; Merck stock outperformed AbbVie.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Eli Lilly and Company
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.
- Nvidia, Eli Lilly, and Booking Holdings are high-growth stocks attracting investor attention, with Eli Lilly being specifically compared to Booking Holdings' stock split.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.